Keep Current with the Latest in Cell Biology Research

APOE2 Mitigates Disease-Related Phenotypes in an Isogenic hiPSC-Based Model of Alzheimer’s Disease

Investigators utilized an isogenic human induced pluripotent stem cell (hiPSC)-based system to demonstrate that conversion of APOE3 to APOE2 greatly reduced the production of amyloid-beta peptides in hiPSC-derived neural cultures.
[Molecular Psychiatry]
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021). APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease. Molecular Psychiatry, 1–18. https://doi.org/10.1038/s41380-021-01076-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Neuroendocrine Control of Appetite and Metabolism

The authors discuss the regulation of appetite and metabolism by hypothalamic neurohormone-expressing cells, with a focus on the distinct contributions of neurohormones and neurotransmitters released by these neurons.
[Experimental & Molecular Medicine]
Yoo, E.-S., Yu, J., & Sohn, J.-W. (2021). Neuroendocrine control of appetite and metabolism. Experimental & Molecular Medicine, 1–12. https://doi.org/10.1038/s12276-021-00597-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Astrocytes in Cocaine Addiction and Beyond

Scientists provide a brief overview of the role of astrocytes in regulating synaptic transmission and neuronal function, and discuss how cocaine influences these astrocyte-mediated mechanisms to induce persistent synaptic and circuit alterations that promote cocaine seeking and relapse.
[Molecular Psychiatry]
Wang, J., Holt, L. M., Huang, H. H., Sesack, S. R., Nestler, E. J., & Dong, Y. (2021). Astrocytes in cocaine addiction and beyond. Molecular Psychiatry, 1–17. https://doi.org/10.1038/s41380-021-01080-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Epithelial Sensing of Microbiota-Derived Signals

The authors highlight the pathways by which intestinal epithelial cells sense microbiota-derived signals and the necessity of these detection pathways in maintaining epithelial barrier integrity.
[Genes & Immunity]
Eshleman, E. M., & Alenghat, T. (2021). Epithelial sensing of microbiota-derived signals. Genes & Immunity, 1–10. https://doi.org/10.1038/s41435-021-00124-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Gene Expression Profiling of Brain Endothelial Cells after Experimental Subarachnoid Hemorrhage

Investigators used gene expression profiling to identify 707 unique genes that were significantly differentially expressed in mouse brain endothelial cells after subarachnoid hemorrhage.
[Scientific Reports]
Tso, M. K., Turgeon, P., Bosche, B., Lee, C. K., Nie, T., D’Abbondanza, J., Ai, J., Marsden, P. A., & Macdonald, R. L. (2021). Gene expression profiling of brain endothelial cells after experimental subarachnoid haemorrhage. Scientific Reports, 11(1), 7818. https://doi.org/10.1038/s41598-021-87301-z Cite
Full Article
Bookmark

No account yet? Register

0
Share

Anti-CLL1 Chimeric Antigen Receptor T Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia

Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Insights into Intrauterine Growth Restriction Based on Maternal and Umbilical Cord Blood Metabolomics

Untargeted nuclear magnetic resonance metabolomics was applied in 84 umbilical cord blood and maternal blood samples obtained from 48 intrauterine growth restriction and 36 appropriate for gestational age deliveries.
[Scientific Reports]
Moros, G., Boutsikou, T., Fotakis, C., Iliodromiti, Z., Sokou, R., Katsila, T., Xanthos, T., Iacovidou, N., & Zoumpoulakis, P. (2021). Insights into intrauterine growth restriction based on maternal and umbilical cord blood metabolomics. Scientific Reports, 11(1), 7824. https://doi.org/10.1038/s41598-021-87323-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Imbalance between Inflammatory and Regulatory Cord Blood B Cells Following Pre-Term Birth

Researchers concluded that, after pre-term birth onset, a shift from immunoregulation towards inflammation takes place in cord blood cells that were reportedly representative of the fetal compartment.
[Journal of Reproductive Immunology]
Busse, M., Redlich, A., Hartig, R., Costa, S.-D., Rathert, H., Fest, S., & Zenclussen, A. C. (2021). Imbalance between inflammatory and regulatory cord blood B cells following pre-term birth. Journal of Reproductive Immunology, 103319. https://doi.org/10.1016/j.jri.2021.103319 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Mutant KRAS Triggers Functional Reprogramming of Tumor-Associated Macrophages in Colorectal Cancer

Mutationally activated KRAS in tumor cells reprograms macrophages to a tumor-associated macrophage-like phenotype via a combination effect of tumor-derived CSF2 and lactate.
[Signal Transduction and Targeted Therapy]
Liu, H., Liang, Z., Zhou, C., Zeng, Z., Wang, F., Hu, T., He, X., Wu, X., Wu, X., & Lan, P. (2021). Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer. Signal Transduction and Targeted Therapy, 6(1), 1–13. https://doi.org/10.1038/s41392-021-00534-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

AzurRx BioPharma Initiates Phase II Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma, Inc. announced that it has initiated its Phase II RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide for the treatment of COVID-19 related gastrointestinal infections.
[AzurRx BioPharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

DESTINY-CRC02 Phase II Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer

Daiichi Sankyo Company, Limited AstraZeneca announced that the first patient was dosed in DESTINY-CRC02, a global Phase II trial evaluating the efficacy and safety of ENHERTU® in patients with HER2 overexpressing locally advanced, unresectable or metastatic colorectal cancer with progression following treatment with standard of care chemotherapy.
[Daiichi Sankyo Company]
Press Release
Bookmark

No account yet? Register

0
Share
Share